Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

NACompletedINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

June 1, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

Empagliflozin 25 MG

Patient will get Empagliflozin 25

DRUG

Sitagliptin 100mg

Patient will get Sitagliptin 100 mg

Trial Locations (1)

Division Of Endocrinology & Diabetes, Medanta The Medicity, Gurgaon

All Listed Sponsors

collaborator

Diabetes & Endocrinology Foundation

UNKNOWN

lead

Medanta, The Medicity, India

OTHER

NCT06187285 - Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia | Biotech Hunter | Biotech Hunter